Glenn Tillotson has 30+ years pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and most recently solithromycin. Glenn has held several key committee positions at the American College of Chest Physicians, he is on the Scientific Steering Committee for the GTCBio the Annual Summit on Anti-infective Partnering and Anaerobe Society of Americas congress. Currently Dr Tillotson has published >150 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine Expert Reviews in Anti-Infective Therapy and F1000.
See more from Glenn on ID Hub:
2018 has seen many research highlights and we gave our Expert Panel the difficult challenge of picking their favorites and explaining why! Find out more about topics from improving pneumonia treatment to pre-exposure prophylaxis with their choices below.
Glenn Tillotson gives us an overview of the 14th Biennial Congress of the Anaerobe Society of the Americas, including updates on the microbiome and new therapies.
Glenn Tillotson tells us about the interesting and rewarding opportunities young scientists could have in the pharmaceutical industry, highlighting how his own perceptions have changed over time.